JPS61109717A - 抗腫瘍剤 - Google Patents
抗腫瘍剤Info
- Publication number
- JPS61109717A JPS61109717A JP23201284A JP23201284A JPS61109717A JP S61109717 A JPS61109717 A JP S61109717A JP 23201284 A JP23201284 A JP 23201284A JP 23201284 A JP23201284 A JP 23201284A JP S61109717 A JPS61109717 A JP S61109717A
- Authority
- JP
- Japan
- Prior art keywords
- administration
- antitumor agent
- leptmycin
- injection
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- YACHGFWEQXFSBS-XYERBDPFSA-N leptomycin B Chemical compound OC(=O)/C=C(C)/C[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)/C=C(\C)/C=C/C[C@@H](C)/C=C(/CC)\C=C\[C@@H]1OC(=O)C=C[C@@H]1C YACHGFWEQXFSBS-XYERBDPFSA-N 0.000 claims description 8
- YACHGFWEQXFSBS-UHFFFAOYSA-N Leptomycin B Natural products OC(=O)C=C(C)CC(C)C(O)C(C)C(=O)C(C)C=C(C)C=CCC(C)C=C(CC)C=CC1OC(=O)C=CC1C YACHGFWEQXFSBS-UHFFFAOYSA-N 0.000 claims description 6
- 229930190887 Leptomycin Natural products 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 abstract description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 abstract description 2
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 abstract description 2
- 229940009456 adriamycin Drugs 0.000 abstract description 2
- 229960004316 cisplatin Drugs 0.000 abstract description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 abstract description 2
- -1 etc. Chemical compound 0.000 abstract description 2
- 238000002347 injection Methods 0.000 abstract description 2
- 239000007924 injection Substances 0.000 abstract description 2
- 238000010255 intramuscular injection Methods 0.000 abstract description 2
- 239000007927 intramuscular injection Substances 0.000 abstract description 2
- 238000010253 intravenous injection Methods 0.000 abstract description 2
- 229960004857 mitomycin Drugs 0.000 abstract description 2
- KPMKNHGAPDCYLP-UHFFFAOYSA-N nimustine hydrochloride Chemical compound Cl.CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 KPMKNHGAPDCYLP-UHFFFAOYSA-N 0.000 abstract description 2
- 238000007911 parenteral administration Methods 0.000 abstract description 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 238000007796 conventional method Methods 0.000 abstract 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 abstract 1
- 229960005420 etoposide Drugs 0.000 abstract 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 208000001382 Experimental Melanoma Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- CWGBFIRHYJNILV-UHFFFAOYSA-N (1,4-diphenyl-1,2,4-triazol-4-ium-3-yl)-phenylazanide Chemical compound C=1C=CC=CC=1[N-]C1=NN(C=2C=CC=CC=2)C=[N+]1C1=CC=CC=C1 CWGBFIRHYJNILV-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 101100005766 Caenorhabditis elegans cdf-1 gene Proteins 0.000 description 1
- 244000207543 Euphorbia heterophylla Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001076084 Matus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pyrane Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP23201284A JPS61109717A (ja) | 1984-11-02 | 1984-11-02 | 抗腫瘍剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP23201284A JPS61109717A (ja) | 1984-11-02 | 1984-11-02 | 抗腫瘍剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61109717A true JPS61109717A (ja) | 1986-05-28 |
| JPH0513133B2 JPH0513133B2 (enrdf_load_stackoverflow) | 1993-02-19 |
Family
ID=16932566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP23201284A Granted JPS61109717A (ja) | 1984-11-02 | 1984-11-02 | 抗腫瘍剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS61109717A (enrdf_load_stackoverflow) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002088383A3 (en) * | 2001-04-27 | 2003-10-09 | Max Planck Gesellschaft | Method and system for identifying targets by nucleocytoplasmic cycling and use thereof |
| WO2004045602A1 (ja) * | 2002-11-20 | 2004-06-03 | Japan Science And Technology Agency | マトリックスメタロプロテアーゼ−9の産生を阻害するための薬剤 |
| JP2011506575A (ja) * | 2007-12-20 | 2011-03-03 | ファルマ・マール・ソシエダード・アノニマ | 抗腫瘍化合物 |
| WO2011100403A1 (en) | 2010-02-10 | 2011-08-18 | Immunogen, Inc | Cd20 antibodies and uses thereof |
| US10538535B2 (en) | 2017-04-27 | 2020-01-21 | Pharma Mar, S.A. | Antitumoral compounds |
-
1984
- 1984-11-02 JP JP23201284A patent/JPS61109717A/ja active Granted
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002088383A3 (en) * | 2001-04-27 | 2003-10-09 | Max Planck Gesellschaft | Method and system for identifying targets by nucleocytoplasmic cycling and use thereof |
| WO2004045602A1 (ja) * | 2002-11-20 | 2004-06-03 | Japan Science And Technology Agency | マトリックスメタロプロテアーゼ−9の産生を阻害するための薬剤 |
| JP2011506575A (ja) * | 2007-12-20 | 2011-03-03 | ファルマ・マール・ソシエダード・アノニマ | 抗腫瘍化合物 |
| US9187445B2 (en) | 2007-12-20 | 2015-11-17 | Pharma Mar, S.A. | Antitumoral compounds |
| US9750759B2 (en) | 2007-12-20 | 2017-09-05 | Pharma Mar, S.A. | Antitumoral compounds |
| US9827257B2 (en) | 2007-12-20 | 2017-11-28 | Pharma Mar, S.A. | Antitumoral compounds |
| WO2011100403A1 (en) | 2010-02-10 | 2011-08-18 | Immunogen, Inc | Cd20 antibodies and uses thereof |
| US10538535B2 (en) | 2017-04-27 | 2020-01-21 | Pharma Mar, S.A. | Antitumoral compounds |
| US11332480B2 (en) | 2017-04-27 | 2022-05-17 | Pharma Mar, S.A. | Antitumoral compounds |
| US11339180B2 (en) | 2017-04-27 | 2022-05-24 | Pharma Mar, S.A. | Antitumoral compounds |
| US11713325B2 (en) | 2017-04-27 | 2023-08-01 | Pharma Mar, S.A. | Antitumoral compounds |
| US12384800B2 (en) | 2017-04-27 | 2025-08-12 | Pharma Mar, S.A. | Antitumoral compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0513133B2 (enrdf_load_stackoverflow) | 1993-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Von Hoff et al. | Phase I clinical investigation of 1, 4-dihydroxy-5, 8-bis {{{2-[(2-hydroxyethyl) amino] ethyl} amino}}-9, 10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione | |
| EP1067941B1 (en) | Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate | |
| JP2002537333A (ja) | 相乗作用性抗腫瘍組成物 | |
| CZ290120B6 (cs) | Sdruľená kompozice paclitaxelu, docetaxelu nebo jejich analogu | |
| ES2282400T3 (es) | Composiciones antitumorales que contienen derivados de taxano. | |
| EP0774255B1 (en) | Use of ursolic acid for the manufacture of a medicament for suppressing metastasis | |
| JPS61109717A (ja) | 抗腫瘍剤 | |
| Harvey et al. | Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer | |
| CN101568338B (zh) | 化合物用于制备治疗白血病药物的用途 | |
| AU774393B2 (en) | Anti-tumor synergetic composition | |
| US20200375943A1 (en) | Cytocidal method of cancer cells selectively in human patients clinically by depletion of l-ascorbic acid, primarily, with its supplementation alternately augmenting its cytocidal effect | |
| CN111773388A (zh) | A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用 | |
| CN111544580B (zh) | 一种抗癌症的药物组合物 | |
| YOSHIDA et al. | Antitumor effect of kazusamycin B on experimental tumors | |
| EP1200099B1 (en) | Synergistic composition comprising daunorubicin derivatives and antimetabolite compounds | |
| Polyzos et al. | Chemotherapy of non small cell lung cancer. A prospectively randomized study of cisplatin-etoposide versus cisplatin-mitomycin-vinblastine | |
| JPH04182427A (ja) | キサントシリンｘジメチルエーテルを含有する抗腫瘍剤 | |
| JPH02235813A (ja) | 抗腫瘍剤 | |
| CN115581703A (zh) | 复方吉西他滨组合物及应用 | |
| OKUMOTO et al. | Increased Lifespan by the Sequential Treatment with Improsulfan and Cyclophosphamide in Rats bearing Yoshida Ascites Sarcoma | |
| Betcher et al. | Idarubicin | |
| KR20050055758A (ko) | 젬시타빈 및 ｚｄ6126을 사용한 조합 요법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |